Two separate studies demonstrated no advantage over standard treatment, and a benefit for secondary prevention was offset by increased bleeding risk.
Idraparinux, a thrombin-dependent inhibitor of factor Xa, is a long-acting, synthetic pentasaccharide that is administered subcutaneously once a week. Now, researchers report the results of efficacy and safety trials of idraparinux, both for treating deep venous thrombosis (DVT) and pulmonary embolism (PE) and for secondary prevention of recurrent venous thromboembolism (VTE).
In two manufacturer-sponsored, open-label studies, 2904 patients with DVT and 2215 with PE were randomly assigned to receive either idraparinux or standard therapy consisting of tinzaparin, enoxaparin, or intravenous heparin adjusted for the partial thromboplastin time (ratio, 1.5 to 2.5), followed by warfarin or acenocoumarol (international normalized ratio, 2.0 to 3.…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association